Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD)

Mechanisms and Innovations

Häftad, Engelska, 2026

2 649 kr

Kommande

Covers detailed disease mechanisms and the full spectrum of immune cell biology, through to advanced clinical applications The book highlights the latest advances in immunotherapy, including cell-based and next-generation treatments. Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD): Mechanisms and Innovations bridges laboratory research with clinical practice, addressing diagnostics, biomarkers and real-world patient care. It tackles current challenges in IBD, such as therapy resistance, the integration of AI and multi-omic approaches. What sets this book apart is its extensive, up-to-date coverage of all immunotherapeutic strategies, such as monoclonal antibodies, cytokine inhibitors, JAK inhibitors, cell-based therapies, and novel targets such as CAR-T cells and immune checkpoint modulators. It also addresses emerging technologies, personalized medicine, resistance mechanisms, safety, and the gut microbiome, providing a holistic view of current and future directions in IBD immunotherapy.

Written and edited by experts in the field, ‘Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD): Mechanisms and Innovations’ provides comprehensive insights into the immunopathogenesis of IBD
Offers detailed descriptions of both established and emerging immunotherapies
Provides a single resource for crucial information on IBD immunity and immunotherapy, from the molecular factors involved to treatment prospects and future directions
Provides an extensive, up-to-date coverage of all immunotherapeutic strategies, such as monoclonal antibodies, cytokine inhibitors, JAK inhibitors, cell-based therapies, together with novel targets such as CAR-T cells and immune checkpoint modulators

Produktinformation

Utgivningsdatum2026-11-22
Mått210 x 270 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor358
FörlagElsevier Science
ISBN9780443458170

Tillhör följande kategorier

Onkologi inom Medicin

Dr Mandlik has been a researcher and lecturer for over 14 years. He is an Assistant Professor in the Department of Pharmaceutics, Bharati Vidyapeeth, Poona College of Pharmacy. Dr Mandlik’s research interests include: drug targeting, nanocarriers for drug delivery systems, and Quality by Design or QbD. Dr Mandlik holds the following degrees: M. Pharm, Ph.D (Pharmacology). Dr Mandlik has been a researcher and lecturer for over 10 years. Dr Mandlik’s research interests include: hepatoprotection; inflammation and immunity; gene transactivation and transrepression; anti-diabetic studies; and toxicity studies

Part 1 Immunity in inflammatory bowel diseases1 Overview of inflammatory bowel diseases: from bench to bedside2 Pathophysiology of inflammatory bowel disease: innate immune system3 Understanding the intestinal epithelial barrier in IBD4 Role of innate and adaptive immunity in IBD5 Role of dendritic cells in pathogenesis of IBD6 Potential role of natural killer cells in pathogenesis of inflammatory bowel disease7 Immunobiology of T-Cells and B-Cells in inflammatory bowel disease8 Immunobiology of intestinal epithelial cells in inflammatory bowel disease9 Immunobiology of monocytes, macrophages, and polymorphonuclear Cells (PMN) in inflammatory bowel disease10 Cytokine networks in the pathophysiology of inflammatory bowel disease11 Role of chemokines in the pathophysiology of inflammatory bowel disease12 Transforming growth factor (TGF)-β, activins and follistatin: A key regulator in inflammatory bowel disease 14 Role of Occludin, Claudin-2, and Zonulin in inflammatory bowel diseasePart B Immunotherapy in inflammatory bowel diseases15 Basics of immunotherapy in inflammatory bowel disease16 Targeting tumor necrosis factor (TNF)-alpha in inflammatory bowel disease17 Integrin inhibition in inflammatory bowel disease18 Janus kinase (JAK) inhibitors in inflammatory bowel disease19 Stem cell and cell-based therapies in inflammatory bowel disease20 Interleukin inhibition: targeting cytokine pathways21 Key molecular targets for antisense therapy in inflammatory bowel disease22 Therapeutic approaches targeting sphingolipids in inflammatory bowel disease23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets24 Immune checkpoint modulation as a therapeutic strategy in inflammatory bowel disease25 Potential targets for chimeric antigen receptor (CAR)-T cells in inflammatory bowel disease26 Personalized medicine in inflammatory bowel disease immunotherapy27 Advances in immunotherapy and emerging agents28 Immunotherapy resistance and management of failure in inflammatory bowel disease29 Safety, long-term outcomes, and side effects of immunotherapy30 Immunotherapy and the gut microbiome in inflammatory bowel disease